eyes.png

Amyotrophic Lateral
Sclerosis (ALS)

Also known as Lou Gehrig's disease, ALS is a nervous system disease that weakens muscles and impacts physical function

The facts

30,000

people living with ALS in the US

$250,000

avg out of pocket cost for caring for a person with ALS

2-5 

years of avg life expectancy

4

drugs are approved by the FDA for ALS (an orphan disease)

90%

of cases occur without family history

Trial construct vs drug efficacy

pills-removebg-preview_edited.png
Is it the failure of the drug or the failure of the trial construct?

Clinical trial subjects symptomatic for less than 24 months is now the standard in ALS/MND (Motor Neuron Disease) clinical trials.

 

“This delay in diagnosis is a challenge to providing patients with early treatment. It is estimated that by the time patients experience ALS signs and symptoms, approximately 50 to 70% of the motor neurons are nonfunctional.”

What we're doing to help

• Research collaborations with pharmaceutical and academic organizations
• Pharmaceutical trials to improve the  study population selection and improve therapeutic efficacy
• Working to develop and quantify EyeStat to be a new biomarker of ALS
 
• Preparing to use EyeStat in Telehealth, Point of Care, and home markets to monitor ALS remotely